The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Patient Derived Xenograft (PDX) Models Market From 2026 To 2030?
The patient derived xenograft (pdx) models market has seen substantial growth recently. This market is expected to expand from $0.47 billion in 2025 to $0.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.8%. Historically, this growth has been driven by the limited predictive capacity of traditional cell line models, an increase in cancer research initiatives, the reliance on animal models for drug testing, a rising demand for translational oncology studies, and the expansion of academic and pharmaceutical research collaborations.
The patient derived xenograft (pdx) models market is projected to experience swift expansion in the coming years. This market is anticipated to reach $0.92 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.0%. Factors contributing to this growth over the forecast period include the increasing uptake of pdx models in precision medicine, greater investment in humanized mouse and rat models, an increase in co-clinical trial programs, the broadening of contract research services providing pdx solutions, and the expanded application of pdx models for assessing immunotherapy and targeted therapies. Key trends for the forecast duration encompass the growing use of pdx models in preclinical drug development, an elevated emphasis on personalized cancer research utilizing pdx models, the expanding incorporation of digital platforms for managing tumor data, the increased deployment of humanized and genetically modified models, and the growing proliferation of co-clinical trials that benefit from pdx models.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17226&type=smp
What Primary Drivers Are Shaping The Patient Derived Xenograft (PDX) Models Market?
The patient-derived xenograft (PDX) models market is projected to expand due to the increasing demand for personalized medicine in the coming years. Personalized medicine involves customizing medical treatments for each patient’s specific characteristics, taking into account factors like genetics, environment, and lifestyle. The growing demand for personalized medicine is attributed to advances in genomic research, which enable tailored treatments based on individual genetic profiles, leading to more effective and targeted healthcare outcomes. Patient-derived xenograft (PDX) models assist personalized medicine by allowing the testing of individual patient tumors to predict treatment responses and tailor therapies accordingly. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit umbrella organization, in 2023, the FDA approved 16 new personalized treatments for rare diseases, a significant increase from six approvals in 2022. Therefore, the demand for personalized medicine continues to drive the patient-derived xenograft (PDX) models market growth.
How Is The Patient Derived Xenograft (PDX) Models Market Organized By Segment Classification?
The patient derived xenograft (pdx) models market covered in this report is segmented –
1) By Type: Mice Models, Rat Models
2) By Technique: Heterotopic Implantation, Orthotropic Implantation
3) By Tumor Type: Gastrointestinal Tumor Models, Lung Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Other Tumor Models
4) By Application: Preclinical Drug Development, Precision Medicine, Co-Clinical Trials, Basic Cancer Research
5) By End-User: Academic And Research Organizations, Contract Research Organizations, Pharmaceutical And Biotechnological Companies, Other End-Users
Subsegments:
1) By Mice Models: Immunodeficient Mice Models (Nude Mice, SCID Mice), Humanized Mice Models, Genetically Modified Mice Models
2) By Rat Models: Immunodeficient Rat Models, Humanized Rat Models, Genetically Modified Rat Models
What Trends Are Affecting The Growth Of The Patient Derived Xenograft (PDX) Models Market?
Leading companies within the patient-derived xenograft (PDX) models market are developing innovative models that incorporate in vivo bioluminescence imaging capabilities, allowing for real-time monitoring of tumor growth. This in vivo bioluminescence imaging aids PDX models by enabling noninvasive, real-time observation of tumor metastasis and treatment responses, thereby enhancing the effectiveness of preclinical research in drug development. For instance, in March 2024, InVitro Research Solutions Private Limited, an India-based Contract Research Organization (CRO), launched a novel orthotopic model of human glioblastoma in NSG-SGM3 mice, utilizing patient-derived xenografts (PDX) and in vivo bioluminescence imaging. This model aims to facilitate personalized treatment for glioblastoma, which is the most common and aggressive type of brain cancer. Such models are essential for understanding glioblastoma biology and evaluating new targeted therapies and immunotherapies to improve patient outcomes.
Who Are The Industry Participants Involved In The Patient Derived Xenograft (PDX) Models Market?
Major companies operating in the patient derived xenograft (pdx) models market are WuXi AppTec Co Ltd, Charles River Laboratories International Inc, The Jackson Laboratory, Inotiv Inc, Taconic Biosciences Inc, Crown Bioscience Inc, Champions Oncology Inc, Certis Oncology Solutions Inc, EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH, InnoSer, Envigo, Oncodesign Services SA, Horizon Discovery Ltd, Pharmatest Services Ltd, Hera BioLabs, Xenopat, Noble Life Sciences, Medicilon, TheraIndx Life Sciences, Invivocue, InVitro Research Solutions Private Limited, NexusPharma, Mediford Corporation, GemPharmatech Co Ltd.
Get The Full Patient Derived Xenograft (PDX) Models Market Report:
Which Region Is The Leading Market For The Patient Derived Xenograft (PDX) Models Market?
North America was the largest region in the patient derived xenograft (PDX) models market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (pdx) models market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Patient Derived Xenograft (PDX) Models Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Patient Derived Xenograft (PDX) Models Market 2026, By The Business Research Company
Healthcare Data Interoperability Market Report 2026
Patient Registry Software Market Report
https://www.thebusinessresearchcompany.com/report/patient-registry-software-global-market-report
Clinical Data Analytics Solutions Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model